Action BHC BAUSCH HEALTH COMPANIES INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Bausch Health Companies Inc.

Actions

BHC

CA0717341071

Marché Fermé - Nyse
Autres places de cotation
 22:00:02 01/05/2024 		Varia. 5j. Varia. 1 janv.
8,75 USD -0,11% Graphique intraday de Bausch Health Companies Inc. +2,22% +9,10%
23/04 Bausch Health en " position plus forte " pour la distribution de Bausch + Lomb, selon RBC MT
23/04 RBC annonce les résultats du premier trimestre de Bausch Health et réduit son objectif à 11 $US MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says
RBC Previews Bausch Health's Q1, Trims Target to US$11
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1
Bausch Health's Issuer Credit Rating Upgraded by S&P
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds
Bausch Health, Canada Inc. - Acne vulgaris treatment PrARAZLO now available to patients through British Columbia PharmaCare public drug plan
Bausch Health Companies - Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029
Bausch Health to Announce First-Quarter 2024 Results on May 2
Bausch wins US appeal to block Alvogen generic of diarrhea drug
Canadian Investment Regulatory Organization Trade Resumption - BHC
Canadian Investment Regulatory Organization Trading Halt - BHC
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BHC
  4. Actualités Bausch Health Companies Inc.
  5. Autres langues